November 2026 • PharmaTimes Magazine • 36-37
// YOUR MOVES //
Brunelcare has appointed Bruce Moore as its new Chair of Trustees, effective from 1 November. He succeeds Graham Russell, who is stepping down for health reasons after holding the position since July 2023.
Bruce is Chief Executive of Housing
21, a national not-for-profit provider of retirement living and extra care housing,
a role he has held since 2013. His career includes senior leadership positions at Hanover Housing Group, Wolverhampton Homes and Anchor Trust. He has also served on the Boards of several housing associations and charities.
Bruce brings extensive experience and
a longstanding connection to Brunelcare, having previously served as a trustee almost 20 years ago.
Bruce Moore said: "I am thrilled to
be joining Brunelcare to help lead the organisation through its next chapter
as Chair. Having previously served as a trustee for the charity almost twenty years ago, I am looking forward to returning in this new role."
"I have long admired the work of Brunelcare and the positive difference it makes to the thousands of people it provides care and support for every day. I look forward to working closely with the Board, Executive Team and colleagues across Brunelcare to uphold its vision of later living that makes the most of every moment."
As Chair, Bruce will work closely with Brunelcare’s leadership team to drive forward its Strategy for 2024–2030. The strategy focuses on delivering great customer service, making homes fit for the future, providing tailored care and support and ensuring Brunelcare is a great place to work and thrive.
Populate, the place management platform owned by mixed-use developer Socius, has appointed Dr Angela Kukula as Director of Science and Innovation. She was previously Chief Executive of MedCity and Director of Life Sciences at London & Partners, where she championed London’s life sciences sector internationally.
Her earlier career included roles as Commercial Director at Chelsea and Westminster Hospital NHS Foundation Trust and positions at the Institute of Cancer Research focused on commercialisation and business growth. She has played a central role in connecting growing companies with investors, research institutions and healthcare partners.
In her new role Angela will expand Populate’s offer in the science and technology sectors. She will advise property owners, research institutions and corporate occupiers on creating ecosystems, commercial partnerships and campus infrastructure that support innovation.
One of her first projects will be the London Cancer Hub. Populate is working with Socius and Aviva Capital Partners, alongside the Institute of Cancer Research and Royal Marsden NHS Foundation Trust, to enhance the campus environment and bring together researchers, clinicians, oncology companies and investors.
Angela explained: "In my career to date I have focused on building the networks and partnerships that enable innovation and growth to happen. At Populate I will take this a step further and help to curate and manage physical places that make collaboration seamless and create a real commercial advantage for businesses."
Mover of the Month
Nuclera has appointed Carl Raimond
as Chief Executive Officer as the company advances its proprietary protein technologies across key life-sciences workflows.
Co-founder and former CEO Dr Michael Chen has transitioned to the role of Chief Scientific and Business Officer, continuing to guide scientific strategy while supporting market development and strategic partnerships.
The leadership change marks a new phase in Nuclera’s evolution, building on more than a decade of work in cell-free protein synthesis, digital microfluidics and protein production.
The combination of Carl’s experience scaling life-sciences businesses with Michael’s scientific leadership will support Nuclera as it expands adoption of its platform across priority applications.
Nuclera is applying its cell-free protein synthesis and digital microfluidics capabilities to accelerate protein science. Current focus areas include full-length IgG antibody screening, challenging membrane protein synthesis and soluble protein expression.
Carl joins Nuclera from Thermo Fisher Scientific, where he served as President of Proteomic Sciences following its acquisition of Olink Proteomics. He previously served as President of Olink Proteomics, helping lead the company through its $3.1 billion acquisition. His earlier career includes senior roles at PerkinElmer, Agilent Technologies and Affymetrix."